(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy...
Stats | |
---|---|
本日の出来高 | 2.77M |
平均出来高 | 881 503 |
時価総額 | 105.77M |
EPS | $-0.0700 ( 2024-02-09 ) |
次の収益日 | ( $-0.0600 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -2.56 |
ATR14 | $0.00200 (0.30%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Mazur Leonard L | Buy | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Mazur Leonard L | Sell | 1 165 048 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Buy | 129 450 | Warrant to Purchase Common Stock |
2024-04-03 | Holubiak Myron Z | Sell | 129 450 | Warrant to Purchase Common Stock |
2024-03-14 | Smith Robert Joseph | Buy | 75 000 | Stock Option (Right to Purchase Common Stock) |
INSIDER POWER |
---|
43.31 |
Last 96 transactions |
Buy: 27 334 255 | Sell: 1 367 765 |
ボリューム 相関
Citius Pharmaceuticals 相関
10 最も正の相関 | |
---|---|
FICS | 0.886 |
HEAR | 0.877 |
RNEM | 0.868 |
VIGI | 0.866 |
NTRSO | 0.865 |
RMRM | 0.861 |
PID | 0.86 |
TCON | 0.856 |
TZOO | 0.856 |
GAINL | 0.854 |
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Citius Pharmaceuticals 相関 - 通貨/商品
Citius Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-194 316 (0.00 %) |
EPS: | $-0.220 |
FY | 2023 |
収益: | $0 |
総利益: | $-194 316 (0.00 %) |
EPS: | $-0.220 |
FY | 2022 |
収益: | $0 |
総利益: | $-179 677 (0.00 %) |
EPS: | $-0.230 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.230 |
Financial Reports:
No articles found.
Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。